Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 2/20 | 0.73 |
| ▸ | TNKS | O95271 | 8/20 | 0.61 |
| ▸ | PARP1 | P09874 | 6/20 | 0.61 |
| ▸ | TNKS2 | Q9H2K2 | 6/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 2/20 | 0.61 |
| ▸ | CSNK2B | P67870 | 2/20 | 0.61 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.61 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.60 |
| ▸ | HPGD | P15428 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.60 |
| ▸ | MAPT | P10636 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.60 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.60 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883775 | 0.85 | FTO (1.00) | FTOTNKSPARP1TNKS2ALDH1A1 | |
| SCHEMBL30000045 | 0.85 | FTO (1.00) | FTOTNKSPARP1TNKS2ALDH1A1 | |
| SCHEMBL19209889 | 0.78 | PTPRS (0.86) | FTOTNKSPARP1TNKS2ALDH1A1 | |
| SCHEMBL7371456 | 0.77 | LCK (0.65) | TNKSPARP1TNKS2ALDH1A1CSNK2A2 | |
| SCHEMBL311820 | 0.77 | FTO (0.78) | FTOTNKSPARP1TNKS2ALDH1A1 | |
| SCHEMBL22821714 | 0.76 | ALDH1A1 (0.74) | FTOTNKSPARP1TNKS2ALDH1A1 | |
| SCHEMBL311795 | 0.76 | ALDH1A1 (0.74) | FTOTNKSPARP1TNKS2ALDH1A1 | |
| SCHEMBL7568626 | 0.76 | TNKS (1.00) | TNKSPARP1TNKS2ALDH1A1CSNK2A2 | |
| SCHEMBL1459318 | 0.76 | ALDH1A1 (1.00) | TNKSPARP1TNKS2ALDH1A1CSNK2A2 | |
| SCHEMBL22821671 | 0.76 | ALDH1A1 (0.65) | FTOTNKSPARP1TNKS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. | 2009-10-15 | — | — | US | disclosed |
| WO-2009018350-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| WO-2009018320-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | LIMERICK BIOPHARMA, INC. (US) | 2009-02-05 | — | — | WO | disclosed |
| US-5705703-A | ENZYME INHIBITORS OF TRANSFERASES | HOFFMANN-LA ROCHE INC. (US) | 1998-01-06 | — | — | US | disclosed |
| US-5633371-A | ENZYME INHIBITORS; TREATMENT OF DEPRESSION AND PARKINSON*S DISEASE | HOFFMANN-LA ROCHE INC. (US) | 1997-05-27 | — | — | US | disclosed |
| US-5476875-A | Catechol derivatives | HOFFMAN-LA ROCHE INC. (US) | 1995-12-19 | — | — | US | disclosed |
| US-5389653-A | Inhibitors of the enzyme catechol-O-methyltransferase; useful as co-medication in treatment of Parkinson's disease | HOFFMAN-LA ROCHE INC. (US) | 1995-02-14 | — | — | US | disclosed |
| US-5236952-A | Inhibit the enzyme catechol-O-methyltransferase; for treatment of Parkinson's disease administered with L-dopa | HOFFMANN-LA ROCHE INC. (US) | 1993-08-17 | — | — | US | disclosed |
| EP-0237929-B1 | 3,5-DISUBSTITUTED PYROCATECHOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1993-06-02 | — | — | EP | disclosed |
| EP-0237929-A1 | 3,5-Disubstituted pyrocatechol derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258939-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | FTO 3629/4885TNKS 1537/4885PARP1 838/4885 |
| US-20110190514-A1 | PYRONE ANALOG COMPOSITIONS AND METHODS | CYP11B2, CYP11B1, GLS2 | FTO 3629/4885TNKS 1537/4885PARP1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.